COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

30,971 Articles (22,604 medRxiv, 8,367 bioRxiv)

Most recent first Previous |  Page 529: Articles 5281-5290  | Next

Protection of hybrid immunity against SARS-CoV-2 reinfection and severe COVID-19 during periods of Omicron variant predominance in Mexico
Gonzalez-Montes, J. A., Zaragoza-Jimenez, C. A., Antonio-Villa, N. E., Fermin-Martinez, C. A., Ramirez-Garcia, D., Vargas-Vazquez, A., Gutierrez-Vargas, R. I., Garcia-Rodriguez, G., Lopez-Gatell, H., Valdes-Ferrer, S. I., Bello-Chavolla, O. Y.
10.1101/2022.12.02.22282981 — Posted: 2022-12-03
Battle of Polio eradication in the Western Pacific Region in the transition to COVID-19 endemicity
Mei, R., Kwok, S. L. L., Lau, E. H. Y., Lo, T. H. K., Wu, J. T., Lin, L. K., Leung, K.
10.1101/2022.11.30.22282954 — Posted: 2022-12-03
Mice Humanized for Major Histocompatibility Complex and Angiotensin-Converting Enzyme 2 with High Permissiveness to SARS-CoV-2 Omicron Replication
Le Chevalier, F., Authie, P., Chardenoux, S., Bourgine, M., Vesin, B., Cussigh, D., Sassier, Y., Fert, I., Noirat, A., Nemirov, K., ANNA, F., BERARD, M., Guinet, F., Hardy, D., Charneau, P., Lemonnier, F., Langa-Vives, F., MAJLESSI, L.
10.1101/2022.12.01.518541 — Posted: 2022-12-02
Viral burdens are associated with age and viral variant in a population-representative study of SARS-CoV-2 that accounts for time-since-infection related sampling bias.
Fryer, H., Golubchik, T., Hall, M. D., Fraser, C., Hinch, R., Ferretti, L., Thomson, L., Nurtey, A., Pellis, L., MackIntyre-Cockett, G., Trebes, A., Buck, D., Piazza, P., Green, A., Lonie, L. J., Smith, D., Bashton, M., Crown, M., Nelson, A., McCann, C. M., Tariq, A., Dos Santos, R. N., Richards, Z., The COVID-19 Genomics UK (COG-UK) consortium, , Bonsall, D., Lythgoe, K.
10.1101/2022.12.02.518847 — Posted: 2022-12-02
Gut microbiota dysbiosis is associated with altered tryptophan metabolism and dysregulated inflammatory response in severe COVID-19
Essex, M., Pascual-Leone, B. M., Löber, U., Kuhring, M., Zhang, B., Bruening, U., Fritsche-Guenther, R., Krzanowski, M., Vernengo, F. F., Brumhard, S., Röwekamp, I., Bielecka, A. A., Lesker, T. R., Wyler, E., Landthaler, M., Mantei, A., Meisel, C., Caesar, S., Thiebeault, C., Corman, V., Marko, L., Suttorp, N., Strowig, T., Kurth, F., Sander, L. E., Li, Y., Kirwan, J. A., Forslund, S. K., Opitz, B.
10.1101/2022.12.02.518860 — Posted: 2022-12-02
Potent Immunogenicity and Broad-Spectrum Protection Potential of Microneedle Array Patch-Based COVID-19 DNA Vaccine Candidates Encoding Dimeric RBD Chimera of SARS-CoV and SARS-CoV-2 Variants
Fan, F., Zhang, X., Zhang, Z., Ding, Y., Wang, L., Xu, X., Pan, Y., Gong, F.-Y., Jiang, L., Kang, L., Kou, Z., Zhao, G., Wang, B., Gao, X.-M.
10.1101/2022.12.01.518127 — Posted: 2022-12-02
BBIBP-CorV (Sinopharm) vaccination- induced immunity is affected by age, gender and prior COVID-19 and activates responses to spike and other antigens
Hasan, Z., Masood, K. I., Qaiser, S., Khan, E., Hussain, A., Ghous, Z., Khan, U., Yameen, M., Hassan, I., Nisar, M. I., Qazi, M. F., Memon, H. A., Ali, S., Baloch, S., Bhutta, Z. A., Veldhoen, M., Simas, J. P., Mahmood, S. F., Hussain, R., Ghias, K.
10.1101/2022.11.30.518633 — Posted: 2022-12-02
SARS-CoV-2 Antibody response to the Sputnik Vaccine in previous infected Patients and non-infected one
Abdulsamad, M., Ebrahim, F., Tabal, S., Bashir, S., Aburgiga, A., Milad, M., Bareem, M.
10.1101/2022.11.30.22282668 — Posted: 2022-12-01
High SARS-CoV-2 seroprevalence in Lagos, Nigeria with robust antibody and cellular responses
Akanmu, S., Herrera, B. B., Chaplin, B., Ogunsola, F., Osibogun, A., Onawoga, F., John-Olabode, S., Akase, I. E., Nwosu, A., Hamel, D. J., Chang, C. A., Kanki, P. J.
10.1101/2022.11.30.22282833 — Posted: 2022-12-01
Pilot Study Demonstrates Benefits of Nursing Home Air Purification on COVID-19 Outcomes
Jutkowitz, E., Shwemaker, P., Reddy, A., Braun, J., Baier, R.
10.1101/2022.12.01.22282978 — Posted: 2022-12-01

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).